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SARS-CoV-2 infection is responsible for the global COVID-19 
outbreak.[1] The World Health Organization declared COVID-19 
a global pandemic on 11 March 2020.[2] In South Africa (SA), the 
first case of COVID-19 was reported on 5 March 2020.[3,4] To limit 
the spread of the disease, the government introduced a national 
lockdown with a five-level COVID-19 alert system, starting with 
alert level 5 on 27 March 2020. This containment measure delayed 
the peak of COVID-19 disease;[4] however, as restrictions eased, most 
of SA experienced its first peak in July 2020.[5]
As of the end of June 2021, SA had >1.8 million laboratory-
confirmed COVID-19 cases.[6] Confirmation of cases is by ampli-
fication and detection of SARS-CoV-2 RNA in respiratory samples, 
using real-time reverse transcription polymerase chain reaction 
(RT-PCR) assays. PCR testing is mostly offered to both symptomatic 
persons and contacts (defined as asymptomatic persons who have 
had close contact with a confirmed COVID-19 case).[7] This testing 
strategy precludes the ability to estimate the true burden of disease 
and importantly cannot detect disease in recovered individuals.
Seroprevalence surveys may provide a better understanding of 
the epidemiology of COVID-19 than PCR testing. Testing to detect 
anti-SARS-CoV-2 antibodies is able to assess the true number of 
infections more accurately. The majority of these antibody studies 
from around the world conducted early in the epidemic revealed 
a pooled SARS-CoV-2 seroprevalence of 3.38% (95% confidence 
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Background. Estimates of prevalence of anti-SARS-CoV-2 antibody positivity (seroprevalence) for tracking the COVID-19 epidemic are 
lacking for most African countries.
Objectives. To determine the prevalence of antibodies against SARS-CoV-2 in a sentinel cohort of patient samples received for routine 
testing at tertiary laboratories in Johannesburg, South Africa.
Methods. This sentinel study was conducted using remnant serum samples received at three National Health Laboratory Service laboratories 
in the City of Johannesburg (CoJ) district. Collection was from 1 August to 31 October 2020. We extracted accompanying laboratory results 
for glycated haemoglobin (HbA1c), creatinine, HIV, viral load and CD4 T-cell count. An anti-SARS-CoV-2 targeting the nucleocapsid (N) 
protein of the coronavirus with higher affinity for IgM and IgG antibodies was used. We reported crude as well as population-weighted and 
test-adjusted seroprevalence. Multivariate logistic regression analysis was used to determine whether age, sex, HIV and diabetic status were 
associated with increased risk for seropositivity.
Results.  A total of 6 477 samples were analysed, the majority (n=5 290) from the CoJ region. After excluding samples with no age or 
sex stated, the model population-weighted and test-adjusted seroprevalence for the CoJ (n=4 393) was 27.0% (95% confidence interval 
(CI) 25.4 - 28.6). Seroprevalence was highest in those aged 45 - 49 years (29.8%; 95% CI 25.5 - 35.0) and in those from the most densely 
populated areas of the CoJ. Risk for seropositivity was highest in those aged 18 - 49 years (adjusted odds ratio (aOR) 1.52; 95% CI 1.13 - 2.13; 
p=0.0005) and in samples from diabetics (aOR 1.36; 95% CI 1.13 - 1.63; p=0.001).
Conclusions.  Our study conducted between the first and second waves of the pandemic shows high levels of current infection among 
patients attending public health facilities in Gauteng Province.
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interval (CI) 3.05 - 3.72).[8] There is a paucity of similar studies in 
Africa.[9,10] A study from Cape Town that examined the seroprevalence 
in a sentinel survey of public sector patients found high seropositivity 
rates, ranging from 31% to 46% in different populations. This study 
was conducted between July and August 2020, after the peak of the first 
wave in Cape Town, and utilised convenience sampling. The majority 
of the patients sampled were attending antenatal or HIV clinical care 
centres and were therefore overwhelmingly female and adult.[11]
SA, the country most severely affected on the African continent, 
has a heavy burden of communicable diseases (especially HIV and 
tuberculosis) as well as non-communicable diseases such as diabetes 
mellitus (DM), hypertension, cancers and chronic kidney disease.[12] 
These may all predispose to severe COVID-19 disease.[13]
Objectives
To estimate the seroprevalence of anti-SARS-CoV-2 antibodies in 
patients visiting public healthcare centres in Gauteng Province, SA.
Methods
Ethics approval
The study was approved by the University of the Witwatersrand 
Human Ethics Committee (ref. no. M2008105).
Study design
This was a cross-sectional sentinel study conducted using remnant 
serum samples received at three National Health Laboratory Service 
laboratories situated in the City of Johannesburg (CoJ) metropolitan 
area. These laboratories receive samples from surrounding public 
sector primary healthcare (PHC) facilities and hospitals.
Sample selection
We selected remnant samples received at the chemistry departments 
at Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani 
Baragwanath Academic Hospital and Helen Joseph Hospital for 
routine chemistry tests. Samples of adequate volume from hospital 
outpatient departments and PHC facilities, received from August 
to October 2020, were selected. Accompanying RT-PCR results for 
SARS-CoV-2, glycated haemoglobin (HbA1c), creatinine, HIV, viral 
load and CD4 T-cell count were included. These were linked to 
demographic information extracted from the Laboratory Information 
System. Specimens from individual patients were tested only once.
Laboratory methods
Anti-SARS-CoV-2 antibody testing was performed on the Roche 
Cobas e604 analyser utilising the Roche Elecsys SARS-CoV-2 
chemiluminescent assay (both Roche Diagnostics, Germany). The 
assay measures total antibodies targeting the nucleocapsid (N) protein 
of the coronavirus, with higher affinity for IgM and IgG antibodies. 
Prior to this survey, the assay was extensively validated utilising 
a well-characterised selection of positive and negative samples 
(N=434), using local RT-PCR-positive symptomatic individuals and 
stored negative sera taken prior to December 2019. In summary, this 
revealed a high cumulative specificity compared with PCR testing 
of 100% and a sensitivity which varied from 47.6% in patients prior 
to day 7 post diagnosis to 90% after 30 days in patients with PCR-
confirmed SARS-CoV-2 infection.[14]
Data preparation
Age categories reported in the 2020 census population estimates 
were used as follows: 0 - 4, 5 - 9, 10 - 14, 15 - 19, 20 - 24, 25 - 29, 
30 - 34, 35 - 39, 40 - 44, 45 - 49, 50 - 54, 55 - 59, 60 - 64, 65 - 69, 
70 - 74, 75 - 79 and ≥80 years. Data without an age or gender value 
were classified as unknown. Patients were identified as HIV-infected 
if either an HIV viral load or a CD4 T-cell count was recorded or if 
samples came from an antiretroviral clinic or HIV ward. Patients 
were classified as diabetic if the sample came from a diabetes clinic 
and/or the HbA1c was ≥6.5%. We divided HIV-infected patients by 
CD4 T-cell count as below the normal reference range (≤500 cells/µL) 
or within the normal reference range (>500 cells/µL). A CD4 T-cell 
count >500  cells/µL was classified as immune reconstitution. The 
HIV viral load data were classified as <1 000 copies/mL (virological 
suppression) and ≥1 000 copies/mL (detectable viraemia). Based on 
whether the health facility description included the word ‘hospital’, 
collected data were classified as either ‘hospital’ or ‘other’ (facility 
type). All data received as text were converted (coded) to numbers.
Statistical analysis
Data were captured on an Excel 365 spreadsheet (Microsoft, USA) 
and analysis was performed using Stata 15 SE statistical software 
(StataCorp, USA). We reported the number of patients by sex, age 
category, month and geographical area (health district or regions for 
the CoJ). We reported the number of patients with a positive SARS-
CoV-2 N-protein IgG result to determine the crude seroprevalence 
with the 95% CI indicated. We reported the same data by facility 
and ward type (Fig. 1A). Furthermore, to improve precision and 
accuracy of our estimates given a non-random sample, we used a 
Bayesian logistic multilevel regression model with post-stratification 
weighting (MRP) that included sex as a fixed effect, and age and 
region as random effects. The multilevel regression and post-
stratification models assume heterogeneity in the prevalence of 
seropositivity in the different regions of the CoJ. The analysis uses 
the sex-age distribution in each of the CoJ regions as weights. After 
estimating population-weighted prevalence, we went further to 
adjust for the assay uncertainty using the multilevel regression and 
post-stratification model, assuming that the observed prevalence 
is a function of assay sensitivity and specificity (more details in 
the supplementary material available at http://samj.org.za/public/
sup/15669.pdf). For this analysis we used a Roche SARS-CoV-2 
antibody assay performance of 93% sensitivity and 99% specificity 
based on assay evaluations.[15,16] In seropositivity prevalence analysis, 
the sensitivity and specificity of the assay are also known to be a 
source of variation and uncertainty in the estimates. The rjags package 
(R Foundation for Statistical Computing, Austria) was used to fit the 
MRP models, and estimates were reported with associated credible 
intervals. Jags uses Markov Chain Monte Carlo (MCMC) to generate 
a sequence of dependent samples from the posterior distribution 
of the parameters. We reported the population-weighted and test 
performance-adjusted SARS-CoV-2 N-protein IgG seroprevalence. 
The model used SA Census 2011 population estimates for the CoJ for 
administration regions A - G by sex and age category.
We compared HbA1c, viral load and CD4 counts between 
seropositive and seronegative samples. The Wilcoxon rank sum 
test was used to assess whether the difference in median values 
was significant. Multivariable logistic regression analysis was used 
to determine whether age, gender, HIV and diabetic status were 
associated with increased risk for seropositivity. Age was categorised as 
<18, 18 - 49 and >49 years. We reported sex as male and female.
COVID-19 hospitalisations were extracted from DATCOV, a 
hospital surveillance system. The DATCOV system was used by 
hospitals for data elements related to admissions and in-hospital 
deaths. For the August - October 2020 period, we received the numbers 
of admissions and in-hospital deaths for the CoJ.
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Results
Supplementary Table S1 (http://samj.org.za/public/sup/15669.pdf) 
shows the patient characteristics and crude seroprevalence. A total 
of 6 477 samples were analysed, of which the majority were collected 
in September 2020 (n=3 347/6 477; 53.7%). Of all the samples, 
5  290 (81.7%) were from the CoJ district, and 3 234 (49.9%) were 
from females; 201 (3.1%) were from children aged ≥4 years, and 
1 091 patients did not have an age stated on the laboratory request 
form. Crude seroprevalence was highest in August and lowest 
in September. While slightly more samples were from patients 
attending hospital than PHC facilities, the crude seroprevalence was 
remarkably similar for both (27.8%; 95% CI 26.3 - 29.3 v. 27.8%; 95% 
CI 26.3 - 29.5, respectively).
The crude seroprevalence in HIV-positive cases was 26.9% (95% 
CI  25.2 - 28.7), and in diabetics 32.3% (95% CI 29.1 - 35.7); 299 
samples were from women attending antenatal clinics, and for 
these the crude seroprevalence was 30.8% (95% CI 25.6 - 36.3) 
(Supplementary Table S2, http://samj.org.za/public/sup/15669.pdf).
To calculate the age- and test-adjusted seroprevalence for the CoJ, 
we excluded all samples for which there was no age or gender, giving 
a final number of 4 393 samples (Fig. 1A).
SARS-CoV-2 N-protein IgG seroprevalence was calculated 
between August and October 2020, which was between the two waves 
in Gauteng (Fig. 1B). The number of SARS-CoV-2 cases peaked at 
104 663 in wave 1 in July 2020 (Fig. 1B). Similarly, there were 87 106 
SARS-CoV-2 cases in January 2021 during wave 2.
Table 1 shows the adjusted seroprevalence. Adjusted seroprevalence 
was higher in males, (30.1 %; 95% CI 26.5 - 33.2) than in females 
(23.5%; 95% CI 19.4 - 26.7). Seropositivity was >20% for all age 
groups. Seroprevalence was highest in those aged 45 - 49 years 
and lowest in those aged ≤4 years. By subdistrict, seropositivity 
was highest in administrative regions E and F, which represent the 
high-density areas of Alexandra, Wynberg, Sandton, Orange Grove, 
Houghton, Inner City and Johannesburg South (Fig. 2).
Trend analysis
Deaths were assessed as a percentage of hospital admissions, and 
these dropped slightly from 21.2% to 14.1% over the study period. At 
the same time, the crude seroprevalence for the CoJ dropped slightly 
from 31.3% to 26.7% (Table 2).
Logistic regression analysis 
We carried out multivariable logistic regression analysis to determine 
whether age, HIV status or DM increased risk for seropositivity 
(Fig. 3). The risk of seropositivity was similar for males and females 
(adjusted odds ratio (aOR) 0.91; 95% CI 0.81 - 1.04; p=0.19). Patients 
aged 18 - 49 years were significantly more likely to be COVID-
19-seropositive than the <18 years age group, with an OR of 1.52 
(95% CI  1.13 - 2.13; p=0.67). Diabetics had an increased risk for 
seropositivity (aOR 1.36; 95% CI 1.13 - 1.63; p=0.001) compared with 
those who were not diagnosed with DM.
Finally, we compared HbA1c levels, CD4 T-cell counts and 
viral load in seropositive and seronegative samples (Supplementary 
Table S3, http://samj.org.za/public/sup/15669.pdf). We showed that 
HbA1c was significantly higher in patients who were seropositive 
for COVID-19 compared with those who tested negative (8.2%; 95% 
CI 6.8 - 11.0 v. 7.5%; 95% CI 6.2 - 9.4, respectively; p=0.02). Median 
(interquartile range) CD4 T-cell counts were higher in seropositive 
patients than in those who were seronegative (625 (396 - 653) cells/
µL v. 576 (302 - 641) cells/µL, respectively; p=0.0007). Viral load was 
lower also in seropositive patients, but this was not significant.
Discussion
We describe a sentinel convenience seroprevalence survey undertaken 
in the Johannesburg metropolitan area in Gauteng, SA. This survey 
was designed to complement other sentinel surveys, most notably 
the study undertaken in Western Cape Province, which mainly 
sampled patients attending routine antenatal and HIV clinical care.[5] 
Purposive sampling was conducted to ensure that male patients and 














































































Seropositive samples, n=1 802
Crude seroprevalence 27.8%
From the City 
of Johannesburg
n=5 290
Seropositive samples, n=1 504
Crude seroprevalence 28.4%
Data with valid age 
and gender values
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Fig. 1. (A) Flow diagram for data analysis indicating how data were prepared. (B) Number of cases reported per month between March 2020 and March 2021 
diagnosed using SARS-CoV-2 PCR in Gauteng Province, with the incidence reported on the secondary y-axis. (PCR = polymerase chain reaction.)
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children were included in our study. Overall, the mean age- and test-
adjusted seroprevalence for SARS-CoV-2 was 27.8% when averaged 
across all participants studied, with slightly higher rates for males 
and peak seropositivity in individuals aged 18 - 49 years. This figure 
was lower than the 40% reported in the Western Cape seroprevalence 
survey, and may reflect the maturity of the Western Cape epidemic, 
which peaked earlier than that in Gauteng. In addition, the high 
numbers of international tourists accessing Cape Town in December 
2019 and January 2020 may have resulted in earlier and more 
widespread seeding than suspected. The figure may also reflect the 
population sampled. A study conducted among volunteers in the 
Western Cape showed that seropositivity was higher in people from 
lower income brackets.[17]
The present survey was conducted from August to October 2020. 
At this time, PCR-confirmed cases of SARS-CoV-2 infection were 
declining, with the first-wave peak having occurred in July 2020.[5] 
The timing of this study is important, because detectable serological 
responses develop at around day 7 and are maximal for IgG after day 
14 post symptom onset. Assuming that the presence of IgG antibodies 
in this study was protective, at least in the short term, the vast majority 
of those attending hospitals were still immunologically naive. The 
seroprevalence is expected to increase with subsequent waves, and a 
recent study of blood donors in SA carried out in January 2021 for 
predefined days showed a seroprevalence of 60% among black African 
donors, with varying figures across provinces.[18] Importantly, our 
study predates the widespread emergence of the novel 501Y.V2 variant, 
which in early studies was associated with higher transmissibility.[19]
Seropositivity in children was not hugely different to that found 
in adults. As of January 2021, confirmed COVID-19 cases in those 
aged <19 years were almost six times lower than those in adults, 
and admissions were even lower. There are limited data on the 
seroprevalence of COVID-19 antibodies in children. A study from 
Bavaria reported similar findings to ours in that antibody positivity 
in children was higher than actual reported cases of COVID-19.[20] 
This has important public health implications for the debates around 
guidelines for the reopening of schools.
The age- and sex-adjusted seroprevalence was highest in the more 
densely populated areas of Johannesburg Inner City, Soweto and 
surrounds, and Alexandra and surrounds. Overcrowding, often poor 
sanitation and the impracticability of social distancing, handwashing 
and mask use are conducive to spread of infection. It has been shown 
that the COVID-19 caseload, per million population and per km2, is 
systematically higher in high-density areas compared with lower-density 
areas.[21] A limitation of the present study is that we do not have any data 
from private laboratories, which serve a different, wealthier population.
Patient comorbidities were considered as an individual predictor 
of antibody production. In HIV-infected individuals for whom data 
were available, seropositivity correlated significantly with improved 
immune reconstitution. This finding indicates that HIV-infected 
individuals are able to produce an antibody response, and may be 
reassuring in suggesting that those who are well controlled will be 
appropriate vaccine candidates.
Our findings of increased risk for COVID-19 infection in diabetics 
as evidenced by the presence of antibodies are in keeping with 



















Fig. 2. The SARS-CoV-2 nucleocapsid (N) protein IgG Bayesian population-
weighted test-adjusted seroprevalence (reported as rate × 100) across 
Johannesburg regions. Suburbs in the City of Johannesburg are arranged 
into the following administrative regions: Region A: Diepsloot, Kya Sands, 
Dainfern, Midrand, Lanseria and Fourways; Region B: Randburg, Rosebank, 
Emmerentia, Greenside, Mellville, Mayfair, Northcliff, Rosebank, Parktown 
and Parktown North; Region C: Roodepoort, Constantia Kloof, Northgate, 
Florida and Braam Fisherville; Region D: Doornkop, Soweto, Dobsonville 
and Protea Glen; Region E: Alexandria, Wynberg, Sandton, Orange Grove 
and Houghton; Region F: Johannesburg central business district (CDB) and 
Johannesburg South; and Region G: Orange Farm, Weilers Farm, Ennerdale, 
Lenasia, Eldorado Park and Protea South (source: http://www.pikitup.co.za/
contact-us/). CIs are calculated with the Tiwari et al.[25] formula.
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Fig. 3. Forest plot reporting the OR for a positive SARS-CoV-2 nucleocapsid 
(N) protein IgG test, for various risk factors, between August and October 
2020 in Gauteng Province (all sites). (OR = odds ratio; CI = confidence 
interval.)
Table 2. Trend analysis of hospital admissions and seroprevalence for the CoJ*
Month Hospital admissions, N Deaths, n (%) Crude seroprevalence, n/N (%) 
August 2020 1 049 222 (21.2) 419/1 340 (31.3)
September 2020 415 69 (16.6) 800/2 883 (27.7)
October 2020 256 36 (14.1) 285/1 067 (26.7)
CoJ = City of Johannesburg.
*5 290 samples were from CoJ. Crude seroprevalence is reported for CoJ here along with hospital admissions and deaths for CoJ only. 
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severe disease for multiple reasons, including compromised innate 
immunity and the underlying inflammatory state that predisposes 
to cytokine storm. COVID-19 infection can also lead to worsening 
glycaemic control. In SA, only ~60% of all diabetics are diagnosed 
and <10% are well controlled.[23] We do not have data on the presence 
of comorbidities in hospitalised patients. However, in view of the 
interaction between infectious diseases such as tuberculosis, HIV and 
now COVID-19, it is imperative that increased attention be paid to 
the detection and management of non-communicable diseases in SA.
Study limitations
A limitation of the study was that it utilised the Roche Elecsys 
kit, which detects antibodies produced against the nucleocapsid. 
These antibodies do not neutralise the virus, and the degree of 
seroprotection cannot be confirmed. Although recent studies have 
suggested that nucleocapsid antibodies correlate with levels of 
neutralising antibodies, this represents an important caveat of this 
study.[24] However, the detection of past infection in these individuals 
will be important in assessing the effectiveness of public health 
and non-pharmacological control methods in SA patients and will 
assist in informing the vaccine roll-out. In addition, it may provide 
information regarding the potential implications of new variant 
mutations in SA, which may have increased infectivity potential. 
Furthermore, we used remnant samples from patients attending 
hospitals or clinics. Some of these patients may have attended for 
COVID-19-related reasons, and we may therefore have overestimated 
community-level seroprevalence. As we did not have clinical details, 
it is possible that the association of higher CD4 T-cell counts in 
seropositive individuals may represent early HIV infection.
Conclusions
Our estimates of seroprevalence, carried out during the first wave 
of the pandemic, are slightly lower than a similar sentinel survey 
from the Western Cape. We showed that almost one in three people 
in the CoJ were infected during the first wave of the COVID-19 
pandemic. Combined with household surveys, these results can be 
used to determine the infection fatality risk, which is a measure of 
the severity of infection. Prevalence estimates are crucial for weighing 
the risks and benefits of future strategies for the next anticipated 
waves of infections. Our findings of high seroprevalences in children, 
in high-density areas and in diabetics have important public health 
implications. The high seroprevalence in people with HIV infection 
portends well for vaccination in this group.
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